2012 NET SALES

 
 
 
 

Longjumeau, 24 January 2013

Net sales up 5.9% in 2012

(in thousands of euros) 2010 2011 2012 % change
Total as of 31 December 158 511 164 544 174 2895,9%
including Pharmaceutical Synthesis 99 379 102 096 110 001 7,7%
including Fine Speciality Chemicals 59 132 62 448 64 288 2,9%

The PCAS Group achieved 5.9% growth in consolidated net sales for 2012 compared with 2011.

Pharmaceutical Synthesis
Net sales are up 7.7% for 2012 compared with 2011, driven by activities based on proprietary technological platforms.

Fine Specialty Chemicals
The Fine Specialty Chemicals business has continued to grow (+2.9% in 2012 versus 2011), despite confirmation of the Fragrance business underperforming.

In view of this increase in sales, it is possible, as of now, to confirm a significant growth in current operating income for 2012 in relation to 2011.

Next date: 2012 results on 20 February 2013

About PCAS :
 
 
Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.
 
 
PCAS_2012netsales:
http://hugin.info/143512/R/1673021/544535.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE
HUG#1673021